April 13, 2026
Biopharma hiring in 2026 is not being shaped by one trend. It is being pulled by three at the same time: a stronger M&A market, regulatory disruption in the US, and a faster shift from AI experimentation to practical deployment. Together, those forces are changing who life sciences companies hire, how fast they hire, and which capabilities now sit closest to growth.
The M&A backdrop is clearly more active than it was a year ago. PwC says strategic dealmaking in biopharma should accelerate in 2026 as companies use disciplined capital deployment and portfolio shaping to secure innovation and offset looming loss-of-exclusivity pressure. Deloitte likewise points to a late-2025 rebound that carried into a cautiously optimistic 2026 outlook, with 193 life sciences transactions totaling $220 billion by the end of November 2025, while EY says $240 billion of life sciences M&A was signed in 2025 and that average deal size rose as buyers prioritized assets that were closer to launch readiness.
That is not just theory. 2026 has already produced visible examples of large and targeted dealmaking: Merck agreed to buy Terns Pharma for $6.7 billion as it works to reduce reliance on Keytruda ahead of future patent loss, Gilead agreed to acquire Tubulis for up to $5 billion to strengthen its oncology pipeline, and GSK agreed to buy 35Pharma for $950 million as part of its push to accelerate new medicines development. Reuters also reported in January that healthcare dealmakers were entering 2026 expecting a new wave of megamergers.
For hiring, that changes the demand mix. In a hotter M&A market, companies do not just need dealmakers. They need talent that can assess, absorb, and scale acquired science. That raises the value of business development, alliance management, search and evaluation, translational medicine, clinical development, regulatory strategy, CMC, tech ops, and post-deal integration leadership. It also favors candidates who can work across functions, because the assets attracting buyers are increasingly targeted, asset-centric, and expected to move quickly toward development or launch. Deloitte’s 2026 outlook explicitly points to continued demand for targeted tuck-in and bolt-on acquisitions, along with buyer preference for derisked assets and adjacent-market growth.
The second force is regulatory uncertainty in the US. In 2025, Reuters reported that the FDA was slated to lose 3,500 employees under a wider HHS restructuring. It also reported that some biotech firms were considering moving early-stage trials outside the US because they were worried layoffs and policy changes could delay regulatory reviews. That matters for hiring because regulatory unpredictability does not reduce the need for talent. It usually shifts it. Companies become more dependent on regulatory affairs leaders, submission strategists, clinical operations teams that can manage multi-region pathways, and senior program managers who can keep timelines moving when the external environment gets shaky.
At the same time, the FDA is not standing still. The agency’s current leadership page shows Martin A. Makary as Commissioner, and recent FDA announcements show the agency is still rolling out programs and approvals, including activity under its Commissioner’s National Priority Voucher pilot. So the story is not that regulation has stopped. It is that the operating environment has become harder to read, which pushes companies to hire for resilience, speed, and regulatory sophistication rather than assuming a steady-state model.
For UK life sciences employers, that creates both opportunity and pressure. Opportunity, because global companies facing more uncertainty in the US may widen their operational footprint and deepen ex-US regulatory, trial, and manufacturing capability. Pressure, because the UK still has to compete for that work. ABPI has warned that UK life sciences foreign direct investment fell 58% from £1.897 billion in 2021 to £795 million in 2023, and that pharmaceutical R&D investment in the UK also fell in 2023. In a separate report, ABPI says domestic upskilling alone will not meet sector needs at the pace required and argues that attracting global talent is essential to the UK’s growth ambitions.
Then there is AI, which is now moving from innovation theater to operating model reality. McKinsey reports that nearly a quarter of life sciences organizations have already deployed gen AI at scale and identifies talent planning, governance, strategy, and change management as key barriers to scaling it further. In another 2025 article, McKinsey argues that faster regulatory submissions will increasingly depend on a mix of redesigned processes, automation, and AI-enabled content generation. That signals a real hiring shift: companies still need deep scientific and regulatory expertise, but they increasingly want that expertise paired with data fluency, workflow redesign skills, and comfort working alongside AI tools.
The UK data points in the same direction. ABPI’s Life Sciences 2035 work says that around 2% of life sciences job postings specifically mention AI skills, rising to 3% in biopharma roles. Meanwhile, a 2026 UK government AI skills report says jobs involving AI activities could rise to around 3.9 million by 2035, but mostly because existing roles will absorb AI responsibilities rather than because entirely new AI-only jobs will appear. That is a crucial hiring signal for life sciences employers: the real shift is not just recruiting AI specialists. It is rewriting core scientific, operational, and commercial roles so that AI capability becomes part of the baseline.
That means the winners in 2026 hiring are likely to be companies that stop treating talent needs in silos. M&A creates urgency around pipeline-building and integration. FDA instability raises the premium on regulatory judgment and execution. AI adoption changes the profile of the workforce needed to move programs faster and run operations more efficiently. Put together, the result is a market where the most valuable candidates are often the ones who can bridge disciplines: regulatory leaders who understand digital workflows, clinical operations talent comfortable with analytics, CMC and manufacturing professionals who can work in more automated environments, and commercial or medical hires who can translate complex science in a more data-driven organization.
For employers across the US and UK, the hiring question in 2026 is no longer simply, “Do we need more people?” It is, “Do we have the right combination of scientific depth, regulatory adaptability, and AI-ready execution?” The companies answering that well are not just filling vacancies. They are building talent pipelines that match where the industry is actually going. And right now, it is going toward more selective deals, more complex regulatory planning, and a workforce expected to do more with technology woven into the job itself.
© All rights reserved